Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats

被引:8
作者
Hayakawa, H
Takagi, K
Takano, YF
Kawamura, Y
Tsuji, A
机构
[1] Toyama Chem Co Ltd, Res Labs, Drug Safety Res Lab, Toyama 9308508, Japan
[2] Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan
关键词
D O I
10.1211/002235702320402071
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The distribution properties of the novel quinolone pazufloxacin (PZFX) in rats were compared with those of sparfloxacin (SPFX) and ofloxacin (OFLX). Following intravenous administration of these quinolones to rats, the distribution volume at steady state (Vd(ss)) of PZFX was found to be 0.945 L kg(-1), whereas for OFLX and SPFX it was 1.83 and 3.42 L kg(-1), respectively. In order to understand this difference in Vd(ss), first the contribution of each tissue to the Vd(ss) using pharmacokinetic parameters was estimated and it was found that the type of tissue contributing the most was muscle. Subsequently, we determined the extent of tissue binding and uptake clearance (CLuptake) in the muscle. The ratio of unbound fraction of plasma to unbound fraction of muscle was almost equal for all quinolones tested, with values of 1.60, 1.52 and 1.32 for PZFX, OFLX and SPFX, respectively. In contrast, the tissue CLuptake of PZFX in the muscle (0.012 mL min(-1) g(-1)) was significantly lower than that of OFLX and SPFX (0.118 and 0.195 mL min(-1) g(-1), respectively). These results suggest that the low Vd(ss) value for PZFX can be attributed to the low CLuptake in the muscle.
引用
收藏
页码:1229 / 1236
页数:8
相关论文
共 21 条
[1]   Application of muscle microdialysis to evaluate the concentrations of the fluoroquinolones pazufloxacin and ofloxacin in the tissue interstitial fluids of rats [J].
Araki, H ;
Ogake, N ;
Minami, S ;
Watanabe, Y ;
Narita, H ;
Tamai, I ;
Tsuji, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (11) :1141-1144
[2]   Characterization of L-carnitine transport into rat skeletal muscle plasma membrane vesicles [J].
Berardi, S ;
Stieger, B ;
Hagenbuch, B ;
Carafoli, E ;
Krähenbühl, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (07) :1985-1994
[3]   Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis [J].
Forrest, A ;
Chodosh, S ;
Amantea, MA ;
Collins, DA ;
Schentag, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 :45-57
[4]  
Furuhata K, 1998, BIOL PHARM BULL, V21, P456
[5]  
HAYAKAWA H, 1999, CHEMOTHERAPY-TOKYO, V47, P88
[6]  
HYATT JM, 1995, CLIN PHARMACOKINET, V28, P1050
[7]  
IMANURA K, 1991, YAKUZAIGAKU S, V51, P144
[8]  
JIUNN HL, 1982, J PHARMACOKINET BIOP, V10, P637
[9]  
MATSUNAGA Y, 1991, ARZNEIMITTEL-FORSCH, V41-2, P747
[10]  
Minami Shinzaburo, 1995, Japanese Journal of Antibiotics, V48, P626